Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: A prospective study

Critical Reviews in Oncology/Hematology

Volumn 75, Issue 3, 2010, Pages 249-256

  Stotter, Anne ^a   Walker, Rosemary ^b  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Breast cancer; Elderly; Endocrine treatment; Tumour markers

Indexed keywords

ANASTROZOLE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P53; PROTEIN PS2; TAMOXIFEN;

AGED; BREAST BIOPSY; BREAST CANCER; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; VAGINA DISCHARGE;

EID: 77955418940     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.10.008     Document Type: Review

References (53)

1. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
2. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
3. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for portmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492.
4. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19:3808-3816.
5. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21:2101-2109.
6. Ellis M.J., Coop A.C., Singh B., et al. Letrozole inhibits tumour proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003, 63:6523-6531.
7. Horobin J.M., Preece P.E., Dewar J.A., Wood R.A.B., Cuschieri A. Long-term follow up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 1991, 78:213-217.
8. Gaskell D.J., Hawkins R.A., de Carteret S., Chetty U., Sangster K., Forrest A.P.M. Indications for primary tamoxifen in elderly women with breast cancer. Br J Surg 1992, 79:1317-1320.
9. Rai S., Stotter A. Management of elderly patients with breast cancer: the time for surgery. ANZJ Surg 2005, 75:863-865.
10. Monypenny I. Presentation of the UK Symptomatic Breast Audit 1.4.2001-31.3.2002. British Association of Surgical Oncology Meeting, autumn 2003.
11. Wyld L., Garg D.K., Kumar I.D., Brown H., Reed M.W.R. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer 2004, 90:1486-1491.
12. Lavelle K., Moran A., Howell A., Bundred N., Campbell M., Todd C. Older women with operable breast cancer are less likely to have surgery. Br J Surg 2007, 94:1209-1215.
13. Hind D., Wyld L., Beverley C.B., Reed M.W. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006 2006, John Wiley & Sons Ltd, Chichester, UK, CD004272.
14. Fennessy M., Bates T., MacRae K., Riley D., Houghton J., Baum M. Late follow-up of a randomised trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004, 91:699-704.
15. Fentiman I.S., Christiaens M.-R., Paridaens R., et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003, 39:309-316.
16. Kenny F.S., Robertson J.F.R., Ellis I.O., Elston C.W., Blamey R.W. Long-term follow-up of elderly patients randomised to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 1998, 7:335-339.
17. Willsher P.C., Robertson J.F.R., Jackson L., Al-Hilaly, Blamey R.W. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. Breast 1997, 6:150-154.
18. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002, 2:101-112.
19. Luqmani Y.A., Ricketts D., Ryall G., Turnbull L., Law M., Coombes R.C. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer 1993, 54:619-623.
20. Stendahl M., Kronblad A., Ryden L., Emdin E., Bengtsson N.O., Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004, 90:1942-1948.
21. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
22. Walker R.A., Lees E., Webb M'B, Dearing S.J. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996, 74:1796-1800.
23. Walker R.A., Dearing S.J. Expression of epidermal growth factor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999, 53:167-176.
24. Hinnis A., Luckett J.C.A., Walker R.A. Survivin is an independent predictor of short term survival in poor prognostic breast cancer patients. Br J Cancer 2007, 96:639-645.
25. Anderson W.F., Chatterjee N., Ershler W.B., Brawley O.W. Estrogen receptor breast cancer phenotype in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002, 76:27-36.
26. Diab S.G., Elledge R.M., Clark G.M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000, 92:550-556.
27. Horwitz K.B., McGuire W.L. Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 1978, 253:2223-2228.
28. Berns E.M., Klijn J.G., van Putten W.L., et al. P53 protein accumulation predicts poor response to tamoxifen therapy in patients with recurrent breast cancer. J Clin Oncol 1998, 16:121-127.
29. Elledge R.M., Green S., Howes L., et al. bcl-2, p53 and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997, 15:1916-1922.
30. Berstein L.M., Zheng H., Yue W., et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 2003, 10:267-277.
31. Dixon J.M., Jackson J., Hills M., et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004, 40:2742-2747.
32. Stendahl M., Ryden L., NordenskjO{double acute}ld B., JO{double acute}nsson P.E., Landberg G., JirstrO{double acute}m K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast patients. Clin Cancer Res 2006, 12:4614-4618.
33. Dowsett M., Allred C., Knox J., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26:1059-1065.
34. Dowsett M., Houghton J., Iden C., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to estrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17:818-826.
35. Ellis M.J., Rosen E., Dressman H., Marks J. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pre-treatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol 2003, 86:301-307.
36. Anderson H., Bulun S., Smith I., Dowsett M. Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 2007, 106:49-54.
37. Dowsett M., Cuzick J., Wale C., Howell T., Houghton J., Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status. A hypothesis-generating study. J Clin Oncol 2005, 23:7512-7517.
38. Henry J.A., Piggott N.H., Mallick U.K., et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 1991, 62:615-622.
39. Rudas M., Lehnert M., Huynh A., et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 2008, 14:1767-1774.
40. McClelland R.A., Gee J.M., O'Sullivan L., et al. P21(WAF1) expression and endocrine response in breast cancer. J Pathol 1999, 188:126-132.
41. Pellikainen M.J., Pekola T.T., Ropponen K.M., et al. P21WAF1 protein expression in invasive breast cancer and its association with p53, AP-2, cell proliferation and prognosis. J Clin Pathol 2003, 56:214-220.
42. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170.
43. Murphy L.C., Niu Y., Snell L., Watson P. Phosph-serine-118 estrogen receptor-α expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 2004, 10:5902-5906.
44. Sarwar N., Kim J.S., Jiang J., et al. Phosphorylation of ER(alpha) at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER(alpha) phosphorylation in breast cancer progression. Endocr Relat Cancer 2006, 13:851-861.
45. Hopp T.A., Weiss H.L., Parra I.S., Cui Y., Osborne C.K., Fuqua S.A. Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004, 10:7490-7499.
46. Palmieri C., Lam E.W., Mansi J., et al. The expression of ERβcx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004, 10:2424-2428.
47. Gee J.M., Robertson J.F., Ellis I.O., Willsher P., McClelland R.A., Hoyle H.B., et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994, 59:619-628.
48. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95:353-361.
49. National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer: diagnosis and treatment (Clinical Guideline 80). London: NICE; 2009. http://www.nice.org.uk/CG80.
50. Gosney M.A. Clinical assessment of elderly people with cancer. Lancet Oncol 2005, 6:790-797.
51. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancer Oncol 2007, 8:1101-1115.
52. Stotter A, Tahir M, Pretorius R, Robinson T. Experiences of a multidisciplinary elderly breast cancer clinic. In: Reed MW, Audisio RA, editors. Management of breast cancer in older women. Springer; in press.
53. Macaskill E.J., Renshaw L., Dixon J.M. Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone-receptor positive breast cancer. Oncologist 2006, 11:1081-1088.